Newsletter Tool

To view this email as a web page, click here

Today's Rundown

Moderna COVID-19 vaccine wins over key FDA panel, setting up potential for second emergency rollout
Lilly and Regeneron COVID-19 antibodies are available all over the U.S. Why aren't they getting to more patients?
Survey: Majority of nursing homes won’t make it next year if COVID-19 operating losses continue
Abbott plans to ship tens of millions of $25, at-home coronavirus tests in early 2021
Pfizer facing 'various challenges' in COVID-19 vaccine manufacturing, dosing: feds
Biopharma roundup: Pfizer says it's not having vaccine production problems
Healthcare roundup: CVS Health to give $250 pandemic bonus to workers
Horizon's Tepezza supply dwindles as manufacturer Catalent pivots to Warp Speed vaccines
From a consolidation boom to telehealth, here are 5 predictions for the hospital industry in 2021
Is COVID-19 really improving pharma's reputation? Takeda survey says not so much

Featured Story

Moderna COVID-19 vaccine wins over key FDA panel, setting up potential for second emergency rollout

By Amirah Al Idrus

It’s not a case of déjà vu. Moderna’s COVID-19 vaccine is following the footsteps of Pfizer and BioNTech’s candidate, snagging the support of an expert panel that voted in favor of its emergency use Thursday afternoon.

Lilly and Regeneron COVID-19 antibodies are available all over the U.S. Why aren't they getting to more patients?

By Eric Sagonowsky

About a month after the FDA issued emergency authorizations for COVID-19 antibodies from Eli Lilly and Regeneron, most of them have gone unused, a federal official said Wednesday. As hospitals and healthcare officials scramble to get the treatments to more people who need them, the companies said they're also involved in efforts to make the drugs more available.

Survey: Majority of nursing homes won’t make it next year if COVID-19 operating losses continue

By Robert King

Two-thirds of nursing homes reported in a recent survey they won't survive next year if losses stemming from the pandemic including higher staffing costs continue.

Abbott plans to ship tens of millions of $25, at-home coronavirus tests in early 2021

By Conor Hale

The FDA authorized a new version of Abbott's card-based test for use in the home with a physician’s prescription—marking the agency’s third home-based test this month.

Pfizer facing 'various challenges' in COVID-19 vaccine manufacturing, dosing: feds

By Arlene Weintraub

Turns out securing enough raw materials to make millions of doses of its COVID-19 vaccine is far from Pfizer's only challenge, government officials said Wednesday. New questions are emerging, including whether doses inadvertently stored at temperatures that are colder than what's recommended are safe to use.

Biopharma roundup: Pfizer says it's not having vaccine production problems

By Eric Sagonowsky,Angus Liu,Kyle Blankenship,Conor Hale,Fraiser Kansteiner

After HHS secretary Alex Azar said Pfizer was working through vaccine production issues, the company refuted his statement. A panel of experts are reviewing Moderna's vaccine application. Plus, a drug from Horizon will run scarce due to COVID-19 vaccine production plans at a contract manufacturer.

Healthcare roundup: CVS Health to give $250 pandemic bonus to workers

By Healthcare Staff

Follow along with the latest COVID-19 news straight from the Fierce Healthcare team.

Horizon's Tepezza supply dwindles as manufacturer Catalent pivots to Warp Speed vaccines

By Fraiser Kansteiner

When Operation Warp Speed told contract manufacturer Catalent to prioritize its COVID-19 vaccine work, the pivot nixed production of Horizon's eye disease med Tepezza—and now, that drug will run short beginning later this month and into 2021, putting patients at risk of stopping treatment.

From a consolidation boom to telehealth, here are 5 predictions for the hospital industry in 2021

By Robert King

From a boom in mergers to changes to the payer mix, here are five expert predictions for the hospital industry going into 2021.

Is COVID-19 really improving pharma's reputation? Takeda survey says not so much

By Beth Snyder Bulik

If you've been thinking pharma might earn a halo with its COVID-19 work, think again. A recent Takeda study finds U.K. consumers' view of the industry has improved only incrementally. Just 17% of adults surveyed in October said they see pharma in a more positive light now.

COVID-19 Tracker